Navigation Links
Low dose of targeted drug might improve cancer-killing virus therapy
Date:6/16/2014

COLUMBUS, Ohio Giving low doses of a particular targeted agent with a cancer-killing virus might improve the effectiveness of the virus as a treatment for cancer, according to a study led by researchers at The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James).

Viruses that are designed to kill cancer cells oncolytic viruses have shown promise in clinical trials for the treatment of brain cancer and other solid tumors. This cell and animal study suggests that combining low doses of the drug bortezomib with a particular oncolytic virus might significantly improve the ability of the virus to kill cancer cells during oncolytic virus therapy.

The research is published in the journal Clinical Cancer Research.

"These findings pave the way for a treatment strategy for cancer that combines low doses of bortezomib with an oncolytic virus to maximize the efficacy of the virus with little added toxicity," says principal investigator Balveen Kaur, PhD, professor and vice chair of research, Department of Neurological Surgery and Radiation Oncology, and a member of the OSUCCC James Translational Therapeutics Program.

"Because bortezomib is already approved by the Food and Drug Administration, a clinical trial could be done relatively quickly to test the effectiveness of the drug-virus combination," Kaur says.

Bortezomib inhibits the activity of proteasomes, structures in cells that break down and recycle proteins. Kaur notes that blocking these "cellular recycling plants" activates a cellular stress response and increases the expression of heat shock proteins. This reaction, which can lead to bortezomib resistance, makes the cells more sensitive to oncolytic virus therapy with little additional toxicity.

For this study, Kaur and her colleagues used a herpes simplex virus-type 1 oncolytic virus. Key technical findings include:

  • One of the overexpressed heat-shock proteins, HSP90, facilitates oncolytic virus replication, enabling the virus to kill more tumor cells;
  • In a glioma model, the combination treatment suppressed tumor growth by 92 percent relative to controls and improved survival (six of eight tumors had completely regressed by day 23 after treatment);
  • Similar outcomes occurred in a head and neck cancer model.

"To our knowledge, this study is the first to show synergy between an oncolytic HSV-1-derived cancer killing virus and bortezomib," Kaur says. "It offers a novel therapeutic strategy that can be rapidly translated in patients with various solid tumors."


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Wexner Medical Center
Source:Eurekalert

Related biology news :

1. New research could provide key to overcoming resistance to HER2 targeted cancer treatments
2. New Penn-designed gel allows for targeted therapy after heart attack
3. Cancer therapy may be too targeted
4. Researchers develop antibody-targeted treatment for recurrent small-cell lung cancer
5. Scientists uncover image of muscular dystrophy defect & design targeted drug candidates
6. Targeted synthesis of natural products with light
7. Targeted treatment can significantly reduce relapse in children with AML leukemia
8. Fruit pest targeted by genomic research
9. Researchers use nanoscale patches to sensitize targeted cell receptors
10. Targeted culling of deer controls disease with little effect on hunting
11. With early, obvious benefit of a targeted cancer drug, should expensive clinical testing continue?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... and PUNE, India , January 12, 2017 ... and Forecasts, 2015 - 2022," projects that the global biometric technology market is expected ... from 2016 to 2022. Continue Reading ... ... ...
(Date:1/11/2017)... 2017  Michael Johnson, co-founder of Visikol Inc. a company originally ... been named to the elite "Forbes 30 Under 30" list in ... people in 20 fields nationwide to be recognized as a leader ... were selected. ... is currently a PhD candidate at Rutgers University. ...
(Date:1/6/2017)... 2017  SomaLogic announced today that it has ... by iCarbonX, the China -based ... Digital Health Ecosystem that can define each person,s ... biological, behavioral and psychological data, the Internet and ... SomaLogic will provide proteomics data and applications expertise ...
Breaking Biology News(10 mins):
(Date:1/24/2017)... ... January 24, 2017 , ... ... PRM, a chronic disease and transitions of care solution for use by healthcare ... to work at the top of their license. Care teams, care managers ...
(Date:1/24/2017)... DURHAM, N.C. , Jan. 24, 2017 ... service and technology, announces that Daniel Eisenman , ... Biosafety Officer. In his new role, ... and manage a forthcoming institutional biosafety committee (IBC) service. ... navigating the IBC landscape. The new IBC service represents ...
(Date:1/24/2017)... 2017 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ) ... to increase the size of the offering by 75% and ... with warrants to purchase 1,842,106 shares of common stock of ... of common stock (the "Exercise Price"), at a price to ... "Public Price"). The warrants have a term of four (4) ...
(Date:1/24/2017)... USA & Geneva, Switerland (PRWEB) , ... January ... ... to announce the first commercially available malaria Plasmodium falciparum culture panels with standard ... falciparum culture panels, which are available in a range of concentrations from six ...
Breaking Biology Technology: